

Eli Lilly and Company



Areas of interest (Novel targets or platforms)

Diabetes

 Type 2 Diabetes mellitus (Glucose Control - Insulins/Glucagon and Incretins), Obesity + co-morbidities (Metabolic control (Glucose +) and novel disease modifiers) and Diabetic Kidney Disease, Heart failure (Diabetic Complications/end organ protection)

Immunology

 Adaptive Immunity (T-Cell, B-Cell Biology; Cytokine signaling); Immune Resolution (checkpoint receptions, TReg Biology, Immunometabolism, Tolerance); Innate Immunity (myeloid cells/neutrophils, dendritic cells, fibrosis). Key disease areas: dermatology, rheumatology, and GI.

Neurodegeneration

 Misfolded proteins, Neuroinflammation, Synaptic function and Proteostasis

Pain and Migraine

Neuropathic Pain and Migraine prophylaxis

Company Contacts

- Sharon Semones
- Semones_Sharon_E@lilly.com
 https://www.lilly.com/partners/scientific-areas-of-interest
- Please visit our current Lilly pipeline:
 - https://www.lilly.com/discovery/ pipeline









